Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
Unless context requires otherwise, references to “we,” “us,” “our,” “BillionToOne,” or “the Company” here refer to BillionToOne, Inc. Overview BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule next-generation sequencing (smNGS) platform achieves what was once thought impossible—detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented Quantitative Counting Templates (QCTs), enabling measurements at the physical limit of detection—the single DNA molecule. This leap forward addresses a fundamental limitation in healthcare—the inability to detect sparse but clinically crucial disease signals in cell-free DNA (cfDNA). Our superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine, overcoming the technical noise that restrains the traditional next-generation sequencing (NGS) testing methods used by other diagnostic companies. We believe our novel smNGS platform technologies combined with our AI-enhanced integrated workflow, allows us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.
Read the full filing description · filed 11 Mar 2026
At a glance
- Sector
- Healthcare
- Industry
- Services-Medical Laboratories
- CEO
- Oguzhan Atay
Source: SEC filings. Information and analytics, not investment advice.